Beta Bionics CEO sells 16,872 shares in tax sale

Beta Bionics, Inc. President & CEO Sean Saint reported an open-market sale of 16,872 shares of common stock at a weighted average price of $12.6071 per share.

Rhea-AI Filing Summary

Beta Bionics, Inc. President & CEO Sean Saint reported an open-market sale of 16,872 shares of common stock at a weighted average price of $12.6071 per share. According to the disclosure, the shares were sold to cover tax withholding obligations tied to vesting restricted stock units, and he now holds 420,937 shares directly.

Insider Trade Summary

Net Seller: 16,872 shares

Net Sell 1 txn

Insider Saint Sean

Role President & CEO

Sold 16,872 shs ($213K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,872	$12.6071	$213K

Holdings After Transaction: Common Stock — 420,937 shares (Direct)

Footnotes (2)

1. F1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.
2. F2. The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 16,872 shares Weighted average sale price: $12.6071 per share Post-transaction holdings: 420,937 shares +1 more

4 metrics

Shares sold 16,872 shares Open-market sale on 2026-06-02

Weighted average sale price $12.6071 per share Common Stock sale

Post-transaction holdings 420,937 shares Shares held directly after sale

Price range of sales $12.30 to $12.93 Individual trade prices within transaction

Key Terms

restricted stock units, weighted average sale price, open-market sale, tax withholding obligations

4 terms

restricted stock units financial

"associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $12.6071"

open-market sale financial

"transaction_action":"open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

tax withholding obligations financial

"sold to cover tax withholding obligations associated with the vesting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beta Bionics (BBNX) report for Sean Saint?

Beta Bionics reported that President & CEO Sean Saint sold 16,872 shares of common stock. The filing states this sale was conducted in the open market and linked to tax withholding obligations on vesting restricted stock units.

Why did Beta Bionics CEO Sean Saint sell 16,872 BBNX shares?

The filing explains the 16,872 shares were sold to cover tax withholding obligations associated with vesting restricted stock units. This indicates the transaction was tied to compensation-related taxes rather than a discretionary liquidation of his equity stake.

At what price were Sean Saint’s BBNX shares sold in the Form 4?

The weighted average sale price was reported as $12.6071 per share. The filing notes the individual sale prices ranged between $12.30 and $12.93, and detailed breakdowns are available to regulators or shareholders upon request.

How many Beta Bionics shares does Sean Saint hold after this transaction?

After the reported sale, Sean Saint directly holds 420,937 shares of Beta Bionics common stock. This post-transaction figure reflects his remaining direct ownership following the sale used to satisfy tax withholding obligations.

How many BBNX shares did Sean Saint sell according to the Form 4?

The Form 4 shows that Sean Saint sold 16,872 shares of Beta Bionics common stock. These shares were sold in an open-market transaction associated with tax withholding on vesting restricted stock units rather than a stand-alone investment decision.

What trading range applied to Sean Saint’s BBNX share sale?

The filing reports a weighted average sale price of $12.6071 per share, with individual trades occurring between $12.30 and $12.93. Full details of the number of shares sold at each price level are available upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 06:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saint Sean

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CALIFORNIA 92618

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/02/2026		S(1)		16,872	D	$12.6071(2)	420,937	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $12.6071 and the range of prices were between $12.30 and $12.93. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)